Search research articles
Contact Us
Filters
Showing results (71-80 of 85) with videos related to
Page
of 9
Sort By:
Cancer Research
|
November 1, 1993
Epidermal growth factor receptor-mediated autocrine and paracrine stimulation of human transitional cell carcinoma
M E Gleave, J T Hsieh, H C Wu, et al.
Molecular Urology
|
November 4, 2000
Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations
N Bruchovsky, L H Klotz, M Sadar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 26, 2001
A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer
K N Chi, M E Gleave, R Klasa, et al.
The New England Journal of Medicine
|
May 1, 1998
Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group
M E Gleave, M Elhilali, Y Fradet, et al.
The Journal of Urology
|
July 18, 2001
Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects
M E Gleave, S L Goldenberg, J L Chin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 30, 2016
A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers
K N Chi, E Y Yu, C Jacobs, et al.
Journal of Cellular Biochemistry. Supplement
|
January 1, 1992
Human prostate cancer model: roles of growth factors and extracellular matrices
L W Chung, W Li, M E Gleave, et al.
British Journal of Cancer
|
October 6, 2012
International multicentre study examining selection criteria for active surveillance in men undergoing radical prostatectomy
L-M Wong, D E Neal, R B Johnston, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 24, 2020
HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies
D J Khalaf, I M Aragón, M Annala, et al.
Prostate Cancer and Prostatic Diseases
|
July 20, 2016
A diagnosis of prostate cancer and pursuit of active surveillance is not followed by weight loss: potential for a teachable moment
M A Liss, J M Schenk, A V Faino, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 85) with videos related to
Sort By:
Page
of 9
Cancer Research
|
November 1, 1993
Epidermal growth factor receptor-mediated autocrine and paracrine stimulation of human transitional cell carcinoma
M E Gleave, J T Hsieh, H C Wu, et al.
Molecular Urology
|
November 4, 2000
Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations
N Bruchovsky, L H Klotz, M Sadar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 26, 2001
A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer
K N Chi, M E Gleave, R Klasa, et al.
The New England Journal of Medicine
|
May 1, 1998
Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group
M E Gleave, M Elhilali, Y Fradet, et al.
The Journal of Urology
|
July 18, 2001
Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects
M E Gleave, S L Goldenberg, J L Chin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 30, 2016
A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers
K N Chi, E Y Yu, C Jacobs, et al.
Journal of Cellular Biochemistry. Supplement
|
January 1, 1992
Human prostate cancer model: roles of growth factors and extracellular matrices
L W Chung, W Li, M E Gleave, et al.
British Journal of Cancer
|
October 6, 2012
International multicentre study examining selection criteria for active surveillance in men undergoing radical prostatectomy
L-M Wong, D E Neal, R B Johnston, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 24, 2020
HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies
D J Khalaf, I M Aragón, M Annala, et al.
Prostate Cancer and Prostatic Diseases
|
July 20, 2016
A diagnosis of prostate cancer and pursuit of active surveillance is not followed by weight loss: potential for a teachable moment
M A Liss, J M Schenk, A V Faino, et al.
Page
of 9